DECEMBER 2020 | VOLUME 1 | SUBSCRIBE

OEM decision makers highlighted the challenges they face and where they seek supplier support in a recent BONEZONE survey.

While 2020 brought unpredictability, it highlighted numerous opportunities for improvement of processes and technologies with digital tools, additive manufacturing and O.R. platforms.

Conducting successful clinical trials will require orthopedic companies to demonstrate flexibility and adaptability in the future.

A lesson that the pandemic has taught Cheryl Blanchard, Ph.D., Anika's CEO, is the need to stay aware of how quickly and dramatically the world can change.

Related: Infographic: CEOs Talk Business Amid COVID

Orthopedics, often resilient in the face of economic turbulence, faces new complexities with COVID-19. Our Advisory Board talks handling the short-term impacts of the pandemic to emerge stronger.

Related: On-Demand Webinar | State of Orthopedics: Expert Advice to Conquer Uncertainty

Did You Miss It?

Cerapedics is one of only two companies with FDA Class III bone graft technology on the market. The company's leadership team shares the long road to commercialization.

The ISO 10993-1 changes have re-emphasized the need for orthopedic companies to understand and characterize the materials, processes and risks associated with medical devices.

The company announced a breakthrough in additive manufacturing with the ability to incorporate locking technology in their Patient Specific Implants.

The clearance brings enhancements to the TSolution One Total Knee Application currently in use in hospitals and ASCs in the U.S.